Until recently, adolescents only had two treatment options for depression. Transcranial magnetic stimulation (TMS), approved by the Food and Drug Administration (FDA) for adolescents in March, now represents a safe and effective third option. While TMS is relatively expensive compared to treatment modalities like pharmaceuticals, payers are increasingly covering the service for teens. Health Care […]
Neuronetics
Transcranial magnetic stimulation (TMS) is becoming a more viable option for the treatment of depression in youth and adults, providing hope for those with treatment-resistant depression. Of the roughly 22 million American adults who experienced a major depressive episode in 2023, about 30% have treatment-resistant depression, meaning that multiple medications have failed to alleviate their […]
Dealmaking in the behavioral health space is slow these days — there’s no arguing that. But there are still plenty of lessons to be learned from the deals that have been completed thus far in 2024. With less to look at, there’s more to see. With fewer deals, we can spend more time taking in […]
Neuronetics (Nasdaq: STIM), a provider of transcranial magnetic stimulation (TMS), has acquired competitor Greenbrook TMS. Neuronetics purchased all of Greenbrook’s outstanding common shares in an all-stock transaction. The deal comes months after Greenbrook was delisted from the Nasdaq Stock Market LLC. “Beyond the strategic benefits, we believe this acquisition will help create a more attractive […]
Sign up
Receive industry updates and breaking news from Behavioral Health Business